Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias [Phase 1]
Clinical trial update for CBX-250 in relapsed or refractory myeloid leukemias (Phase 1) that is currently recruiting at Crossbow Therapeutic…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients [Phase 2]
Phase 2 study evaluating de-escalation by discontinuing venetoclax and azacitidine in AML patients who are responding to therapy.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation [Phase 1]
Phase 1 trial evaluating the combination of SNDX-5613 and gilteritinib for relapsed or refractory FLT3-mutated acute myeloid leukemia, inclu…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms [NA]
This clinical trial update describes a randomization study to identify the best treatment intensity for less fit adults with acute myeloid l…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation [Phase 2]
A Phase 2 clinical trial is evaluating enasidenib as maintenance therapy after allogeneic stem cell transplantation in patients with IDH2-mu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML [Phase 2]
Phase 2 global trial evaluating safety, efficacy, and pharmacokinetics of midostaurin in combination with chemotherapy for newly diagnosed p…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy [Phase 2]
This clinical trial update reports a Phase 2 study of ziftomenib for patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia w…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS [Phase 1]
This clinical trial update notes a Phase 1 study of CD33 FPBMC in patients with measurable residual disease positive acute myeloid leukemia …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax [Phase 2]
Phase 2 trial update evaluating olutasidenib in relapsed IDH1-mutated acute myeloid leukemia patients who have previously received venetocla…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders [Phase 2]
Phase 2 clinical trial evaluating cord blood transplant in children and young adults with blood cancers and select non-malignant disorders; …
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE [Phase 2]
Phase 2 clinical trial evaluating dasatinib monotherapy in AML patients refractory to venetoclax-azacitidine; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). [Phase 1, Phase 2]
The document updates on an ongoing clinical trial of GYA01 (CART84) for relapsed/refractory acute myeloid leukemia and T-cell acute lymphobl…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML [Phase 1]
Phase 1 trial to assess the safety and tolerability of Ziftomenib in combination with Venetoclax/Azacitidine, Venetoclax alone, or 7+3 with …
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Tazemetostat and Palbociclib With CPX-351for R/R AML [Phase 1]
A Phase 1 trial from Thomas Jefferson University is evaluating a triple combination of tazemetostat, palbociclib, and CPX-351 for recurrent …
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Venetoclax Basket Trial for High Risk Hematologic Malignancies [Phase 1]
A Phase 1 Venetoclax basket trial across multiple high-risk hematologic malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial update: venetoclax plus ASTX727 is being studied for relapsed, refractory, or newly diagnosed acute myeloid leukemia …
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML [Phase 1]
A Phase 1 trial of CRD3874-SI for relapsed or refractory acute myeloid leukemia has been suspended.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Venetoclax in Patients With MDS or AML in Relapse After AHSCT [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating venetoclax in patients with myelodysplastic syndromes or acute myeloid leukemia relapsing after all…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies [Phase 1]
Phase 1 clinical trial update describing the completion of a study evaluating HLA-mismatched microtransplantation without immunosuppressive …
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Long-Term Follow-up Study
Long-term follow-up study of relapsed/refractory non-Hodgkin lymphoma is currently enrolling by invitation, sponsored by Caribou Biosciences…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia
Pfizer is conducting a safety-focused clinical trial of Mylotarg (gemtuzumab ozogamicin) in adults with acute myeloid leukemia, and the stud…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) [Phase 2]
This is a Phase 2 clinical trial update evaluating strategies to reduce graft-versus-host disease in donor blood stem cell transplant patien…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases [NA]
This entry reports an ongoing clinical trial evaluating myeloablative preparative regimens for umbilical cord blood transplantation across s…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. [Phase 2]
A Phase 2 trial is evaluating whether adding ivosidenib to oral azacitidine (Onureg) improves outcomes in patients over 55 with IDH1-mutated…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) [Phase 1]
Phase Ib/Phase 1 clinical trial evaluating azacitidine, venetoclax, and allogeneic NK cells in acute myeloid leukemia, currently recruiting.